In recent years, the use of anti-EGFR mAbs has played an increasing role in the treatment of several solid tumour types including non-small-cell lung carcinoma (NSCLC), colorectal cancer (CRC), and head and neck squamous cell carcinoma (HNSCC) in which KRAS mutation is not detected. Here, EGFR is linked to head and neck squamous cell carcinoma.